Division of Hematology and Oncology, Leipzig University Hospital, Leipzig, Germany;
Blood. 2013 Oct 3;122(14):2433-42. doi: 10.1182/blood-2012-12-472183. Epub 2013 Aug 23.
The transcription factor CCAAT enhancer binding protein α (C/EBPα) is a master regulator in granulopoiesis and is frequently disrupted in acute myeloid leukemia (AML). We have previously shown that C/EBPα exerts its effects by regulating microRNAs (miRs) such as miR-223 and miR-34a. Here, we confirm miR-30c as a novel important target of C/EBPα during granulopoiesis. Thus, wild-type C/EBPα-p42 directly upregulates miR-30c expression, whereas C/EBPα-p30, found in AML, does not. miR-30c is downregulated in AML, especially in normal karyotype AML patients with CEBPA mutations. An induced C/EBPα knockout in mice leads to a significant downregulation of miR-30c expression in bone marrow cells. We identified NOTCH1 as a direct target of miR-30c. Finally, a block of miR-30c prevents C/EBPα-induced downregulation of Notch1 protein and leads to a reduced CD11b expression in myeloid differentiation. Our study presents the first evidence that C/EBPα, miR-30c, and Notch1 together play a critical role in granulocytic differentiation and AML, and particularly in AML with CEBPA mutations. These data reveal the importance of deregulated miRNA expression in leukemia and may provide novel biomarkers and therapeutic targets in AML.
转录因子 CCAAT 增强子结合蛋白 α(C/EBPα)是粒细胞生成中的主要调节因子,并且在急性髓细胞白血病(AML)中经常受到干扰。我们之前已经表明,C/EBPα 通过调节 microRNA(miRs)如 miR-223 和 miR-34a 来发挥其作用。在这里,我们确认 miR-30c 是粒细胞生成过程中 C/EBPα 的一个新的重要靶标。因此,野生型 C/EBPα-p42 可直接上调 miR-30c 的表达,而 AML 中发现的 C/EBPα-p30 则不能。miR-30c 在 AML 中下调,特别是在具有 CEBPA 突变的正常核型 AML 患者中。在小鼠中诱导的 C/EBPα 敲除导致骨髓细胞中 miR-30c 表达的显著下调。我们确定 NOTCH1 是 miR-30c 的直接靶标。最后,miR-30c 的阻断可防止 C/EBPα 诱导的 Notch1 蛋白下调,并导致髓样分化中 CD11b 表达减少。我们的研究首次提供了证据表明,C/EBPα、miR-30c 和 Notch1 一起在粒细胞分化和 AML 中,特别是在具有 CEBPA 突变的 AML 中发挥关键作用。这些数据揭示了白血病中失调的 miRNA 表达的重要性,并可能为 AML 提供新的生物标志物和治疗靶标。